Efficacy and Challenges of Bortezomib for Adult Refractory TTP-A Case Report
摘要
Thrombotic Thrombocytopenic Purpura (TTP) is a rare but life threatening condition. Therapeutic plasma exchange (PLEX) remains the mainstay treatment - adjuvant immunosuppressant therapy with rituximab is also required in some patients despite this some patient remain refractory. Bortezomib has been suggested through case reports as an adjuvant therapy for refractory TTP. However, challenges exist regarding its use.
引用本文（GB/T 7714）
Ryan Low. Efficacy and Challenges of Bortezomib for Adult Refractory TTP-A Case Report[J]. Open Access Blood Research & Transfusion Journal, 2017.
引文网络
本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。